Institution
AstraZeneca (Italy)
Recent research
- Health & Medicine
Initial Changes in eGFR during Treatment with Balcinrenone and Dapagliflozin
Introduction: The novel non-steroidal mineralocorticoid receptor antagonist balcinrenone in combination with dapagliflozin reduced urinary albumin-to-creatinine ratio (UACR) over 12 weeks in the MIRO-CKD phase 2 trial in chronic kidney disease (CKD) and induced a modest acute eGF...
- BiologyOpen access
Abstract Background Evidence remains limited on disease journey for transthyretin (ATTR) amyloidosis in China. This study aims to analyse China data from OverTTuRe, an observational, retrospective, multi-country cohort study. Methods Data were extracted from medical records (2013...
- BiologyOpen access
Next‐Generation Manufacturing: The Evolving Role of Biocatalysis in AstraZeneca
Biocatalysis is becoming a strategic manufacturing capability at AstraZeneca, enabling selective transformations under milder conditions and with the potential to reduce waste and resource intensity relative to conventional routes. This review summarizes how AstraZeneca is embedd...
- Health & Medicine
Tozorakimab to Prevent COPD Exacerbations
BACKGROUND: Many patients with chronic obstructive pulmonary disease (COPD) have exacerbations despite receiving standard-of-care inhaled maintenance therapy. Dysregulated interleukin-33 signaling is implicated in the pathogenesis of COPD. Tozorakimab is a monoclonal antibody tha...
- Health & MedicineOpen access
In this post hoc analysis of the ANNEXa-I trial (n = 434), we evaluated non-contrast computed tomography (NCCT) markers of hematoma expansion (HE) in factor Xa inhibitor (FXai) -associated intracerebral hemorrhage (ICH). At least one NCCT marker was present in 72.1%, and HE (≥12....
- Climate & EnvironmentOpen access
ABSTRACT Beyond its relevance for evolutionary biology and genetics, hybridisation is increasingly recognised as an ecological process that can modify community structure, yet the demographic contribution of admixed individuals in natural primary‐producer systems remains poorly r...
- Health & MedicineOpen access
Clinical trials report no increased malignancy risk with benralizumab in severe asthma; however, trial populations are highly selective. To better define real-world safety, malignancy risk was compared among patients treated with benralizumab, other (non-benralizumab) biologics,...